Luna Innovations (LUNA) 10-Q 6 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'LUNA	'
Entity Registrant Name	'LUNA INNOVATIONS INC	'
Entity Central Index Key	'0001239819	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	15,049,698

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$14,430,156	$7,778,541
Accounts receivable, net	5,267,953	5,408,281
Inventory, net	3,400,132	3,346,177
Prepaid expenses	675,933	708,974
Other current assets	220,207	70,208
Total current assets	23,994,381	17,312,181
Property and equipment, net	1,917,164	2,060,709
Intangible assets, net	180,718	288,475
Other assets	1,995	42,710
Total assets	26,094,258	19,704,075
Current Liabilities:	'	'
Current portion of long-term debt obligation	1,000,000	1,500,000
Current portion of capital lease obligation	69,675	66,617
Accounts payable	1,508,790	1,401,764
Accrued liabilities	3,458,456	3,546,585
Deferred credits	404,487	691,424
Total current liabilities	6,441,408	7,206,390
Long-term debt obligation	0	625,000
Long-term lease obligation	57,662	110,307
Total liabilities	6,499,070	7,941,697
Commitments and contingencies	'	'
Stockholders’ equity:	'	'
Preferred stock, par value $ 0.001, 1,321,514 shares authorized, issued and outstanding at September 30, 2014 and December 31, 2013	1,322	1,322
Common stock, par value $ 0.001, 100,000,000 shares authorized, 15,049,698 and 14,527,335 shares issued at September 30, 2014 and December 31, 2013	15,387	14,842
Less treasury stock at cost, 22,725 shares at September 30, 2014 and zero at December 31, 2013	-32,221	0
Additional paid-in capital	63,824,535	62,756,571
Accumulated deficit	-44,213,835	-51,010,357
Total stockholders’ equity	19,595,188	11,762,378
Total liabilities and stockholders’ equity	$26,094,258	$19,704,075

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	1,321,514	1,321,514
Preferred stock, shares issued	1,321,514	1,321,514
Preferred stock, shares outstanding	1,321,514	1,321,514
Treasury stock, shares	22,725	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	15,049,698	14,527,335
Common stock, shares outstanding	15,026,973	14,527,335

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:	'	'	'	'
Technology development revenues	$3,067,022	$3,130,206	$8,961,909	$8,564,743
Products and licensing revenues	2,303,508	1,568,646	6,108,799	5,070,441
Total revenues	5,370,530	4,698,852	15,070,708	13,635,184
Cost of revenues:	'	'	'	'
Technology development costs	2,379,105	2,282,061	6,793,061	6,676,133
Products and licensing costs	908,175	739,646	2,654,305	2,322,776
Total cost of revenues	3,287,280	3,021,707	9,447,366	8,998,909
Gross Profit	2,083,250	1,677,145	5,623,342	4,636,275
Operating expense:	'	'	'	'
Selling, general and administrative	2,329,713	2,447,972	7,551,512	7,986,541
Research, development and engineering	473,527	531,185	1,707,190	1,932,966
Total operating expense	2,803,240	2,979,157	9,258,702	9,919,507
Operating loss	-719,990	-1,302,012	-3,635,360	-5,283,232
Other income/(expense):	'	'	'	'
Other income, net	0	78,162	111,431	271,306
Interest expense	-21,275	-42,654	-80,942	-150,614
Total other (expense)/income	-21,275	35,508	30,489	120,692
Loss from continuing operations, before income taxes	-741,265	-1,266,504	-3,604,871	-5,162,540
Income tax benefit	-274,709	-491,925	-1,419,882	-2,033,694
Net loss from continuing operations	-466,556	-774,579	-2,184,989	-3,128,846
Operating (loss)/income from discontinued operations, net of $0.0 million, $0.3 million, $0.0 million and $0.6 million of related income taxes	-52	394,556	-28,127	900,179
(Loss)/gain on sale, net of $0.3 million, $0.2 million, $1.6 million and $1.5 million of related income taxes	-277,562	-233,889	9,093,268	3,448,270
(Loss)/income from discontinued operations, net of income taxes	-277,614	160,667	9,065,141	4,348,449
Net (loss)/income	-744,170	-613,912	6,880,152	1,219,603
Preferred stock dividend	26,760	26,166	83,630	76,161
Net (loss)/income attributable to common stockholders	($770,930)	($640,078)	$6,796,522	$1,143,442
Net loss per share from continuing operations:	'	'	'	'
Basic (in dollars per share)	($0.03)	($0.05)	($0.15)	($0.22)
Diluted (in dollars per share)	($0.03)	($0.05)	($0.15)	($0.22)
Net (loss)/income per share from discontinued operations:	'	'	'	'
Basic (in dollars per share)	($0.02)	$0.01	$0.61	$0.30
Diluted (in dollars per share)	($0.02)	$0.01	$0.53	$0.26
Net (loss)/income per share attributable to common stockholders:	'	'	'	'
Basic (in dollars per share)	($0.05)	($0.04)	$0.46	$0.08
Diluted (in dollars per share)	($0.05)	($0.04)	$0.40	$0.07
Weighted average common shares and common equivalent shares outstanding:	'	'	'	'
Basic (in shares)	15,016,429	14,441,707	14,821,619	14,285,829
Diluted (in shares)	15,016,429	16,809,498	17,185,369	16,593,102

Consolidated_Statements_of_Ope1

Consolidated Statements of Operations (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Gain on sale, related income taxes	$281,462	$233,889	$1,604,883	$1,491,677
Operating income (loss) from discontinued operations, tax	$52	$255,905	($18,077)	$590,181

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows used in operating activities	'	'
Net income	$6,880,152	$1,219,603
Adjustments to reconcile net income to net cash used in operating activities	'	'
Depreciation and amortization	491,066	711,375
Share-based compensation	738,802	896,554
Gain on sale of discontinued operations, net of income taxes	-9,093,268	-3,448,270
Bad debt expense	0	124,810
Tax benefit from utilization of loss from current year operations	-1,437,958	-1,448,260
Change in assets and liabilities	'	'
Accounts receivable	139,950	1,880,545
Inventory	-92,320	-438,592
Other current assets	-170,857	26,931
Other assets	40,715	91,376
Accounts payable and accrued expenses	-98,920	-600,471
Deferred credits	-286,937	-274,746
Net cash used in operating activities	-2,889,575	-1,259,145
Cash flows provided by investing activities	'	'
Acquisition of property and equipment	-199,532	-161,519
Intangible property costs	-197,683	-187,928
Proceeds from sale of discontinued operations, net of fees	10,927,268	4,522,460
Net cash provided by investing activities	10,530,053	4,173,013
Cash flows (used in)/provided by financing activities	'	'
Payments on capital lease obligations	-49,587	-40,993
Payment of debt obligations	-1,125,000	-1,125,000
Purchase of treasury stock	-32,221	0
Proceeds from the exercise of options and warrants	217,945	96,329
Net cash used in financing activities	-988,863	-1,069,664
Net increase in cash and cash equivalents	6,651,615	1,844,204
Cash and cash equivalents—beginning of period	7,778,541	6,340,461
Cash and cash equivalents—end of period	14,430,156	8,184,665
Supplemental disclosure of cash flow information	'	'
Cash paid for interest	73,917	142,188
Dividend on preferred stock, 59,469 shares of common stock issuable for the nine months ended September 30, 2014 and 2013	83,631	76,161
Cash paid for income taxes	$150,000	$14,010

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Statement of Cash Flows [Abstract]	'	'
Dividend on preferred stock, shares of common stock issuable	59,469	59,469

Basis_of_Presentation_and_Sign

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation and Significant Accounting Policies	'
	Basis of Presentation and Significant Accounting Policies
	Nature of Operations
	Luna Innovations Incorporated (“we,” “Luna Innovations” or the “Company”) is incorporated in the State of Delaware and headquartered in Roanoke, Virginia. We develop, manufacture and market fiber optic sensing, test and measurement products and are focused on bringing new and innovative technology solutions to measure, monitor, protect and improve critical processes in the aerospace, automotive, energy, composite, telecommunications and defense industries. We are organized into two main groups, which work closely together to turn ideas into products: our Technology Development segment and our Products and Licensing segment. Our business model is designed to accelerate the process of bringing new and innovative technologies to market. We have a history of net losses from continuing operations from 2005 through the nine months ended September 30, 2014. We have historically managed our liquidity through cost reduction initiatives, debt financings, capital market transactions and asset sales.
	Since the second half of 2008, the increased turmoil in the U.S. and global capital markets and a global slowdown of economic growth created a substantially more difficult business environment. Our ability to access the capital markets may be limited. Economic and market conditions may not improve significantly during the remainder of 2014 and could get worse.
	Although there can be no guarantees, we believe that our current cash balance will provide adequate liquidity for us to meet our working capital needs over the next twelve months.
	Unaudited Interim Financial Information
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United Stated of America (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Act of 1934. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. The unaudited consolidated financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management reflect all adjustments, consisting of only normal recurring accruals considered necessary to present fairly our financial position at September 30, 2014, results of operations for the three and nine months ended September 30, 2014 and 2013, and cash flows for the nine months ended September 30, 2014 and 2013. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.
	The consolidated interim financial statements, including our significant accounting policies, should be read in conjunction with the audited Consolidated Financial Statements and the notes thereto for the year ended December 31, 2013, included in the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission on April 10, 2014 and amended on April 15, 2014.
	Consolidation Policy
	Our consolidated financial statements are prepared in accordance with U.S. GAAP and include the accounts of the Company and our wholly owned subsidiaries. We eliminate from our financial results all significant intercompany transactions. We do not have any investments in entities we believe are variable interest entities for which we are the primary beneficiary.
	Fair Value Measurements
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between marketplace participants. Various valuation approaches can be used to determine fair value, each requiring different valuation inputs. The following hierarchy classifies the inputs used to determine fair value into three levels:
	•	Level 1—Quoted prices for identical instruments in active markets
	•	Level 2—Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets
	•	Level 3—Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable
	The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value because of the short-term nature of these instruments. The carrying value of our debt approximates fair value, as we consider the floating interest rate on our credit facilities with Silicon Valley Bank to be at market. Certain nonfinancial assets and liabilities are measured at fair value on a nonrecurring basis in accordance with U.S. GAAP. This includes items such as nonfinancial assets and liabilities initially measured at fair value in a business combination and nonfinancial long-lived asset groups measured at fair value for an impairment assessment. In general, nonfinancial assets including intangible assets and property and equipment are measured at fair value when there is an indication of impairment and are recorded at fair value only when any impairment is recognized.
	Use of Estimates
	The preparation of our consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may differ from such estimates and assumptions.
	Earnings Per Share
		Net loss per share from continuing													Net (loss)/income attributable to common stockholders
		operations
		For the three months ended September 30,							For the nine months ended September 30,						For the three months ended September 30,						For the nine months ended September 30,
		2014				2013			2014			2013			2014			2013			2014		2013
	Numerator:
	Net loss from continuing operations	$	(466,556	)		$	(774,579	)	$	(2,184,989	)	$	(3,128,846	)
	Net (loss)/income attributable to stockholders														$	(770,930	)	$	(640,078	)	$	6,796,522	$	1,143,442
	Denominator:
	Basic weighted average common shares outstanding	15,016,429				14,441,707			14,821,619			14,285,829			15,016,429			14,441,707			14,821,619		14,285,829
	Weighted average common stock equivalents from assumed exercise of stock options and restricted stock awards	—				—			—			—			—			—			688,065		730,703
	Convertible preferred stock	—				—			—			—			—			—			1,321,514		1,321,514
	Preferred stock dividends	—				—			—			—			—			—			354,171		255,056
	Diluted weighted average common shares outstanding	15,016,429				14,441,707			14,821,619			14,285,829			15,016,429			14,441,707			17,185,369		16,593,102
	Basic net loss per share from continuing operations	$	(0.03	)		$	(0.05	)	$	(0.15	)	$	(0.22	)
	Diluted net loss per share from continuing operations	$	(0.03	)		$	(0.05	)	$	(0.15	)	$	(0.22	)
	Basic net (loss)/income per share attributable to common stockholders														$	(0.05	)	$	(0.04	)	$	0.46	$	0.08
	Diluted net (loss)/income per share attributable to common stockholders														$	(0.05	)	$	(0.04	)	$	0.4	$	0.07
	Weighted-average anti-dilutive shares related to:
	Outstanding stock options	4,448,259				5,322,656			4,086,208			5,322,686			4,448,259			5,322,656			3,005,297		4,095,725
	Convertible preferred stock	1,321,514				1,321,514			1,321,514			1,321,514			1,321,514			1,321,514			—		—
	Preferred stock dividends	373,994				274,879			354,171			255,056			373,994			274,879			—		—
	Restricted stock	330,160				261,257			290,394			219,759			330,160			261,257			—		—
	Carilion warrants	366,000				366,000			366,000			366,000			366,000			366,000			366,000		366,000
	The weighted-average anti-dilutive shares shown in the foregoing table were not included in the computation of diluted net loss from continuing operations and net income per share attributable to common stockholders. For reporting periods in which we have reported net income attributable to common stockholders, weighted-average anti-dilutive shares comprise stock options that have exercise prices above the average stock price for the period. For reporting periods in which we have a net loss from continuing operations, the weighted-average anti-dilutive shares comprise shares that would have been dilutive had we had net income from continuing operations (e.g., convertible preferred stock, preferred stock dividends, restricted stock, warrants and stock options that have exercise prices below the average stock price for the period), plus the number of stock options that would be anti-dilutive had we had a net income from continuing operations.
	Share-Based Compensation
	We recognize share-based compensation expense based upon the fair value of the underlying equity award on the date of the grant. For restricted stock awards and restricted stock units, we recognize expense based upon the price of our underlying stock at the date of the grant. We have elected to use the Black-Scholes option pricing model to value any option or warrant awards granted. We amortize share-based compensation for such awards on a straight-line basis over the related service period of the awards taking into account the effects of the employees’ expected exercise and post-vesting employment termination behavior. To compute the volatility used in this model we use the historical volatility of our common stock over the expected life of options granted. The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. The expected life and estimated post-employment termination behavior is based upon historical experience of homogeneous groups within our company. We also assume an expected dividend yield of zero for all periods, as we have never paid a dividend on our common stock and do not have any plans to do so in the future.
	The fair value of each option granted during the nine months ended September 30, 2014 and 2013 was estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions:
		Nine Months Ended September 30, 2014		Nine Months Ended September 30, 2013
	Risk-free interest rate	2.14%		1.27 - 2.34%
	Expected life of options (in years)	7.5		7.5
	Expected stock price volatility	106%		108%
	A summary of the activity for our 2003 Stock Plan and 2006 Equity Incentive Plan is presented below for the nine months ended September 30, 2014:
		Options Outstanding											Options Exercisable
		Number of			Price per Share		Weighted			Aggregate			Number of		Weighted			Aggregate
		Shares			Range		Average			Intrinsic			Shares		Average			Intrinsic
							Exercise			Value (1)					Exercise			Value (1)
							Price								Price
	Balance, January 1, 2014	5,279,229			$0.35 - $6.55		$	2.11		$	784,154		4,012,378		$	2.28		$	697,826
	Granted	915,952			$1.37 - $1.53		$	1.42
	Exercised	(276,586	)		$0.35 - $1.27		$	0.79
	Canceled	(1,470,336	)		$0.35 - $6.55		$	1.4
	Balance, September 30, 2014	4,448,259			$0.35 - $6.55		$	1.92		$	494,279		3,055,457		$	2.11		$	459,175
	-1	The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only. The aggregate intrinsic value is based on the closing price of our common stock on the NASDAQ Capital Market, as applicable, on the respective dates.
	At September 30, 2014, the outstanding stock options to purchase an aggregate of 4.4 million shares had a weighted average remaining contractual term of 6.3 years, and the exercisable stock options to purchase an aggregate of 3.1 million shares had a weighted average remaining contractual term of 5.0 years.
For each of the three months ended September 30, 2014 and 2013, we recognized $0.3 million, and for the nine months ended September 30, 2014, and 2013, we recognized $0.7 million and $0.9 million, respectively, in share-based compensation expense, which is included in our selling, general and administrative expense in the accompanying consolidated financial statements. We expect to recognize $1.6 million in share-based compensation expense over the weighted average remaining service period of 1.6 years for stock options outstanding as of September 30, 2014.
During the nine months ended September 30, 2014, we repurchased 22,725 shares of common stock, at an average share price of $1.42 per share, pursuant to the election of the holders in order to satisfy tax withholding requirements with respect to the vesting of their respective restricted stock awards.
Intangible Assets and Other Long Lived Assets
Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair market value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair market value, less cost to sell.
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year presentation.
Accounting Renouncements
The FASB issued ASU 2014-09 "Revenue from Contracts with Customers" clarifying the method used to determine the timing and requirements for revenue recognition on the statements of income. Under the new standard, an entity must identify the performance obligations in a contract, the transaction price and allocate the price to specific performance obligations to recognize the revenue when the obligation is completed. The amendments in this update also require disclosure of sufficient information to allow users to understand the nature, amount, timing and uncertainty of revenue and cash flow arising from contracts. The new accounting guidance is effective for interim and annual periods beginning after December 15, 2016. We are analyzing the impact of this new standard and, at this time, cannot estimate the impact of adoption on revenue or net income. We plan to adopt ASU 2014-09 effective January 1, 2017.

Discontinued_Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2014
Discontinued Operations and Disposal Groups [Abstract]	'
Discontinued Operations	'
	Discontinued Operations
	On March 1, 2013, we completed the sale of our Secure Computing and Communications group ("SCC"), which was part of our Technology Development segment, to an unaffiliated third party for a gross sales price of $6.1 million of cash. Prior to the sale, SCC provided innovative solutions designed to secure critical technologies within the U.S. government. SCC conducted applied research and provided services to the government in this area, with its revenues primarily derived from U.S. government contracts and purchase orders. Of the purchase price, we received approximately $5.4 million at closing and $110,000 on December 31, 2013. During December 2013, an additional $475,000 in purchase price was released to us from escrow and the remaining $125,000 was released to us in October 2014. In connection with the sale, we incurred approximately $0.9 million in transaction costs that included various charges related to investment banker and legal fees. In addition, the acquirer entered into a sublease with us for the facilities historically occupied by SCC through April 30, 2014 for a total of $106,000 for the nine months ended September 30, 2014. In the transaction, we sold the equipment, contracts and intellectual property associated with SCC. Approximately 20 employees of SCC transferred to the acquirer. Included in the transaction were current assets of approximately $0.2 million and long term assets with a net book value of approximately $0.1 million, at February 28, 2013.We recorded an aggregate after-tax gain on the sale of SCC of $3.3 million or $0.20 per diluted share in our results of operations for the year ended December 31, 2013.
	We have reported the results of operations of SCC as discontinued operations in our consolidated financial statements. We allocated a portion of the consolidated tax expense to discontinued operations based on the ratio of the discontinued group’s income or loss before allocations. Through December 31, 2013, we continued to act on behalf of the purchaser and bill the government for certain contracts that have not yet been transferred by the government to the purchaser. We recorded these amounts as revenues, with an offsetting amount as cost of revenues, within (loss)/income from discontinued operations.
	On January 21, 2014, we completed the sale of our medical shape sensing business, which was part of our Products and Licensing segment, to an unaffiliated third party for a gross sales price of up to $30.0 million, of which $12.0 million in cash has been received, up to $8.0 million is payable to us in the future upon the accomplishment by the buyer of certain technical specifications, and we may receive up to $10.0 million in potential future royalties. We had been engaged since 2007 in various development projects developing a fiber optic-based shape sensing and position tracking system to be integrated in the buyer's products. Also as part of the transaction, the buyer has hired certain employees of the company, many of whom were historically engaged in this development project. In connection with this sale, we incurred approximately $1.3 million in transaction costs that included various charges related to investment banker and legal fees and a bonus to a former employee who was hired by the buyer. Included in the transaction were current and long term assets with a net book value of approximately $0.3 million on January 20, 2014. Our medical shape sensing business accounted for 12% of our revenues and 10% of our costs of revenues for the year ended December 31, 2013. We recorded an after-tax loss on the sale of medical shape sensing business of $0.3 million, or $0.02 per diluted share, for the three months ended September 30, 2014, due to intraperiod allocation of income taxes in the third quarter of 2014 and an after-tax gain of $9.1 million, or 0.53 per diluted share, for the nine months ended September 30, 2014.
	We have reported the results of operations of SCC and our medical shape sensing business as discontinued operations in our consolidated financial statements. We allocated a portion of the consolidated tax expense to discontinued operations based on the ratio of the discontinued groups' income before allocations.
	The key components of income from discontinued operations were as follows:
		Three Months Ended						Nine Months Ended
		30-Sep-14			30-Sep-13			30-Sep-14			30-Sep-13
	Net revenues	$	—		$	1,578,308		$	—		$	4,343,391
	Cost of revenues	—			927,847			46,204			2,623,286
	Operating expenses	—			—			—			229,745
	Income/(loss) before income taxes	—			650,461			(46,204		)	1,490,360
	Allocated tax expense/(benefit)	52			255,905			(18,077		)	590,181
	Operating (loss)/income from discontinued operations, net of income taxes	(52		)	394,556			(28,127		)	900,179
	(Loss)/gain on sale, net of $0.3 million, $0.2 million, $1.6 million and $1.5 million of related income taxes	(277,562		)	(233,889		)	9,093,268			3,448,270
	(Loss)/income from discontinued operations, net of income taxes	$	(277,614	)	$	160,667		$	9,065,141		$	4,348,449

Inventory

Inventory	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory	'
	Inventory
	Inventory consists of finished goods, work-in-process and parts valued at the lower of cost (determined on the first-in, first-out basis) or market. We provide reserves for estimated obsolescence or unmarketable inventory equal to the difference between the cost of the inventory and the estimated market value based upon assumptions about future demand and market conditions.
	Components of inventory are as follows:
		September 30,		December 31,
		2014		2013
	Finished goods	$	637,054	$	719,574
	Work-in-process	452,304		361,754
	Parts	2,518,037		2,339,595
		3,607,395		3,420,923
	Less: Inventory reserves	207,263		74,746
	Total inventory, net	$	3,400,132	$	3,346,177

Accrued_Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Accrued Liabilities	'
	Accrued Liabilities
		30-Sep-14		31-Dec-13
	Accrued compensation	$	2,111,858	$	2,205,612
	Accrued sub-contracts	309,570		297,510
	Accrued professional fees	20,885		279,991
	Accrued income tax	162,105		13,143
	Deferred rent	72,477		102,569
	Royalties	344,383		291,442
	Warranty reserve	61,850		56,700
	Claims reserve	—		92,167
	Accrued liabilities - other	375,328		207,451
	Total Accrued Liabilities	$	3,458,456	$	3,546,585

Debt

Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	Debt
	Silicon Valley Bank Credit Facilities
	We currently have a Loan and Security Agreement with Silicon Valley Bank (“SVB”) in which we have a term loan with an original borrowing amount of $6.0 million (the “Term Loan”). The Term Loan is to be repaid by us in 48 monthly installments, plus accrued interest payable monthly in arrears, and unless earlier terminated, matures on the earlier of either May 1, 2015 or an event of a default under the loan agreement. The Term Loan carries a floating annual interest rate equal to SVB’s prime rate then in effect plus 2%, which is currently 6%. We may repay amounts due under the Term Loan at any time with no penalties.
	In addition to the terms and conditions of the Term Loan, the loan and security agreement also previously included a revolving credit facility (the "Line of Credit") with a maximum borrowing capacity of $1.0 million. The interest rate on the Line of Credit was SVB’s prime rate plus 1.25%, payable monthly in arrears, and we were required to pay an unused Line of Credit fee of one-quarter of one percent (0.25%), payable monthly. The Line of Credit had a maturity date of May 17, 2014, and we did not renew the Line of Credit upon its maturity.
	Amounts due under the Term Loan are secured by substantially all of our assets, including intellectual property, personal property and bank accounts.
	On March 21, 2013, we entered into a Fourth Loan Modification Agreement with SVB that replaced the existing financial covenants with a single covenant that we maintain a minimum cash balance of $5.0 million with SVB. Effective on January 21, 2014, in connection with our sale of our medical shape sensing business, this covenant was modified to reduce the required minimum cash balance to $3.0 million. The Term Loan also requires us to observe a number of operational covenants, including protection and registration of intellectual property rights, and certain customary negative covenants. As of September 30, 2014, we were in compliance with all covenants under the Term Loan.
	In addition, the Term Loan contains customary events of default, including nonpayment of principal, interest or other amounts, violation of covenants, material adverse change, an event of default under any subordinated debt documents, incorrectness of representations and warranties in any material respect, bankruptcy, judgments in excess of a threshold amount, and violations of other agreements in excess of a threshold amount. If any event of default occurs SVB may declare due immediately all borrowings under the Term Loan and foreclose on the collateral. Furthermore, an event of default under the Term Loan would result in an increase in the interest rate on any amounts outstanding. As of September 30, 2014, there were no events of default on our Term Loan.
	On October 15, 2014 we applied for a letter of credit in the amount of $500,000 with SVB, to be provided in connection with our new Blacksburg, Virginia lease, effective October 1, 2014.
	The balance under the Term Loan at September 30, 2014, was $1.0 million, all of which was classified as short-term.

Capital_Stock_and_Additional_P

Capital Stock and Additional Paid-in Capital	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Capital Stock and Additional Paid-in Capital	'
	Capital Stock and Additional Paid-in Capital
	The following details our equity transactions during the nine months ended September 30, 2014:
		Preferred Stock		Common Stock		Treasury Stock				Additional
										Paid-in
										Capital
		Shares	$	Shares	$	Shares		$		$
	Balances, December 31, 2013	1,321,514	1,322	14,527,335	14,842	—		—		62,756,571
	Exercise of stock options	—	—	276,586	277	—		—		217,668
	Share-based compensation	—	—	268,500	209	—		—		766,724
	Stock dividends to Carilion Clinic(1)	—	—	—	59	—		—		83,572
	Purchase of treasury stock					(22,725	)	(32,221	)
	Balances, September 30, 2014	1,321,514	1,322	15,072,421	15,387	(22,725	)	(32,221	)	63,824,535
	-1	The stock dividends payable in connection with Carilion Clinic’s Series A Preferred Stock will be issued subsequent to September 30, 2014. For the period from January 12, 2010, the original issue date of the Series A Preferred Stock, through September 30, 2014, the Series A Preferred Stock issued to Carilion has accrued $793,807 in dividends. The accrued and unpaid dividends as of September 30, 2014 will be paid by the issuance of 373,994 shares of our common stock upon Carilion’s written request.

Operating_Segments

Operating Segments	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Operating Segments	'
	Operating Segments
	Our operations are divided into two operating segments—“Technology Development” and “Products and Licensing”.
	The Technology Development segment provides applied research to customers in our areas of focus. Our engineers and scientists collaborate with our network of government, academic and industry experts to identify technologies and ideas with promising market potential. We then compete to win fee-for-service contracts from government agencies and industrial customers who seek innovative solutions to practical problems that require new technology. The Technology Development segment derives its revenues primarily from services.
	The Products and Licensing segment derives its revenues from product sales, funded product development and technology licenses. This segment previously included our medical shape sensing business, which was sold on January 21, 2014, and the amounts below do not include the revenues, expenses and assets of our medical shape sensing business.
	Through September 30, 2014, our Chief Executive Officer and his direct reports collectively represented our chief operating decision makers, and they evaluated segment performance based primarily on revenues and operating income or loss. The accounting policies of our segments are the same as those described in the summary of significant accounting policies (see Note 1 to our Financial Statements, “Organization and Summary of Significant Accounting Policies,” presented in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission on April 10, 2014 and amended on April 15, 2014).
	The table below presents revenues and operating loss for reportable segments not including discontinued operations:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
		(unaudited)						(unaudited)
	Revenues:
	Technology development revenues	$	3,067,022		$	3,130,206		$	8,961,909		$	8,564,743
	Products and licensing revenues	2,303,508			1,568,646			6,108,799			5,070,441
	Total revenues	$	5,370,530		$	4,698,852		$	15,070,708		$	13,635,184
	Technology development operating loss	$	(299,980	)	$	(259,486	)	$	(2,835,120	)	$	(599,303	)
	Products and licensing operating loss	(420,010		)	(1,042,526		)	(800,240		)	(4,683,929		)
	Total operating loss	$	(719,990	)	$	(1,302,012	)	$	(3,635,360	)	$	(5,283,232	)
	Depreciation, technology development	$	49,592		$	86,413		$	160,327		$	272,570
	Depreciation, products and licensing	$	37,247		$	43,304		$	109,037		$	161,426
	Amortization, technology development	$	38,641		$	61,563		$	131,615		$	173,140
	Amortization, products and licensing	$	29,022		$	30,851		$	90,087		$	104,239
	The table below presents assets for reportable segments:
		September 30,			December 31,
		2014			2013
	Total segment assets:
	Technology development	$	14,902,005		$	10,208,433
	Products and licensing	11,192,253			9,495,642
	Total	$	26,094,258		$	19,704,075
	Property plant and equipment, and intangible assets, technology development	$	1,198,066		$	1,217,083
	Property plant and equipment, and intangible assets, products and licensing	$	899,816		$	1,132,101
	There are no material inter-segment revenues for any period presented.
	The United States Government accounted for approximately 60% and 62% of total consolidated revenues for the three months ended September 30, 2014 and 2013, respectively, and 60% and 56% of total consolidated revenues for the nine months ended September 30, 2014 and 2013, respectively.
	International revenues (customers outside the United States) accounted for approximately 15% and 16% of total consolidated revenues for the three months ended September 30, 2014 and 2013, respectively, and 16% and 23% of total consolidated revenues for the nine months ended September 30, 2014 and 2013, respectively.

Contingencies_and_Guarantees

Contingencies and Guarantees	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies and Guarantees	'
	Contingencies and Guarantees
	We are from time to time involved in certain legal proceedings in the ordinary course of conducting our business. While the ultimate liability pursuant to these actions cannot currently be determined, we believe these legal proceedings will not have a material adverse effect on our financial position or results of operations.
	In the fourth quarter of 2013 we executed two non-cancelable purchase orders totaling $1.4 million for multiple shipments of tunable lasers to be delivered over an 18-month period beginning in 2013. At September 30, 2014, approximately $0.7 million of this commitment remained.
	In September 2014, we received a preliminary audit report from the Defense Contract Audit Agency, or DCAA, with respect to our 2007 incurred cost submission and questioning $0.8 million of claimed costs that the DCAA believes are expressly unallowable under the Federal Acquisition Regulations and, therefore, subject to potential penalty. We have not been informed of any actual claim for penalty by the Defense Contract Management Agency and intend to contest such claim if received.
	We have entered into indemnification agreements with our officers and directors, to the extent permitted by law, pursuant to which we have agreed to reimburse the officers and directors for legal expenses in the event of litigation and regulatory matters. The terms of these indemnification agreements provide for no limitation to the maximum potential future payments. We have a directors and officers insurance policy that may, in certain instances, mitigate the potential liability and payments.

Basis_of_Presentation_and_Sign1

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Nature of Operations	'
	Nature of Operations
	Luna Innovations Incorporated (“we,” “Luna Innovations” or the “Company”) is incorporated in the State of Delaware and headquartered in Roanoke, Virginia. We develop, manufacture and market fiber optic sensing, test and measurement products and are focused on bringing new and innovative technology solutions to measure, monitor, protect and improve critical processes in the aerospace, automotive, energy, composite, telecommunications and defense industries. We are organized into two main groups, which work closely together to turn ideas into products: our Technology Development segment and our Products and Licensing segment. Our business model is designed to accelerate the process of bringing new and innovative technologies to market. We have a history of net losses from continuing operations from 2005 through the nine months ended September 30, 2014. We have historically managed our liquidity through cost reduction initiatives, debt financings, capital market transactions and asset sales.
	Since the second half of 2008, the increased turmoil in the U.S. and global capital markets and a global slowdown of economic growth created a substantially more difficult business environment. Our ability to access the capital markets may be limited. Economic and market conditions may not improve significantly during the remainder of 2014 and could get worse.
	Although there can be no guarantees, we believe that our current cash balance will provide adequate liquidity for us to meet our working capital needs over the next twelve months.
Unaudited Interim Financial Information	'
	Unaudited Interim Financial Information
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United Stated of America (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Act of 1934. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. The unaudited consolidated financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management reflect all adjustments, consisting of only normal recurring accruals considered necessary to present fairly our financial position at September 30, 2014, results of operations for the three and nine months ended September 30, 2014 and 2013, and cash flows for the nine months ended September 30, 2014 and 2013. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.
	The consolidated interim financial statements, including our significant accounting policies, should be read in conjunction with the audited Consolidated Financial Statements and the notes thereto for the year ended December 31, 2013, included in the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission on April 10, 2014 and amended on April 15, 2014.
Consolidation Policy	'
	Consolidation Policy
	Our consolidated financial statements are prepared in accordance with U.S. GAAP and include the accounts of the Company and our wholly owned subsidiaries. We eliminate from our financial results all significant intercompany transactions. We do not have any investments in entities we believe are variable interest entities for which we are the primary beneficiary.
Fair Value Measurements	'
	Fair Value Measurements
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between marketplace participants. Various valuation approaches can be used to determine fair value, each requiring different valuation inputs. The following hierarchy classifies the inputs used to determine fair value into three levels:
	•	Level 1—Quoted prices for identical instruments in active markets
	•	Level 2—Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets
	•	Level 3—Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable
	The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value because of the short-term nature of these instruments. The carrying value of our debt approximates fair value, as we consider the floating interest rate on our credit facilities with Silicon Valley Bank to be at market. Certain nonfinancial assets and liabilities are measured at fair value on a nonrecurring basis in accordance with U.S. GAAP. This includes items such as nonfinancial assets and liabilities initially measured at fair value in a business combination and nonfinancial long-lived asset groups measured at fair value for an impairment assessment. In general, nonfinancial assets including intangible assets and property and equipment are measured at fair value when there is an indication of impairment and are recorded at fair value only when any impairment is recognized.
Use of Estimates	'
	Use of Estimates
	The preparation of our consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may differ from such estimates and assumptions.
Earnings Per Share	'
	Earnings Per Share
		Net loss per share from continuing												Net (loss)/income attributable to common stockholders
		operations
		For the three months ended September 30,						For the nine months ended September 30,						For the three months ended September 30,						For the nine months ended September 30,
		2014			2013			2014			2013			2014			2013			2014		2013
	Numerator:
	Net loss from continuing operations	$	(466,556	)	$	(774,579	)	$	(2,184,989	)	$	(3,128,846	)
	Net (loss)/income attributable to stockholders													$	(770,930	)	$	(640,078	)	$	6,796,522	$	1,143,442
	Denominator:
	Basic weighted average common shares outstanding	15,016,429			14,441,707			14,821,619			14,285,829			15,016,429			14,441,707			14,821,619		14,285,829
	Weighted average common stock equivalents from assumed exercise of stock options and restricted stock awards	—			—			—			—			—			—			688,065		730,703
	Convertible preferred stock	—			—			—			—			—			—			1,321,514		1,321,514
	Preferred stock dividends	—			—			—			—			—			—			354,171		255,056
	Diluted weighted average common shares outstanding	15,016,429			14,441,707			14,821,619			14,285,829			15,016,429			14,441,707			17,185,369		16,593,102
	Basic net loss per share from continuing operations	$	(0.03	)	$	(0.05	)	$	(0.15	)	$	(0.22	)
	Diluted net loss per share from continuing operations	$	(0.03	)	$	(0.05	)	$	(0.15	)	$	(0.22	)
	Basic net (loss)/income per share attributable to common stockholders													$	(0.05	)	$	(0.04	)	$	0.46	$	0.08
	Diluted net (loss)/income per share attributable to common stockholders													$	(0.05	)	$	(0.04	)	$	0.4	$	0.07
	Weighted-average anti-dilutive shares related to:
	Outstanding stock options	4,448,259			5,322,656			4,086,208			5,322,686			4,448,259			5,322,656			3,005,297		4,095,725
	Convertible preferred stock	1,321,514			1,321,514			1,321,514			1,321,514			1,321,514			1,321,514			—		—
	Preferred stock dividends	373,994			274,879			354,171			255,056			373,994			274,879			—		—
	Restricted stock	330,160			261,257			290,394			219,759			330,160			261,257			—		—
	Carilion warrants	366,000			366,000			366,000			366,000			366,000			366,000			366,000		366,000
	The weighted-average anti-dilutive shares shown in the foregoing table were not included in the computation of diluted net loss from continuing operations and net income per share attributable to common stockholders. For reporting periods in which we have reported net income attributable to common stockholders, weighted-average anti-dilutive shares comprise stock options that have exercise prices above the average stock price for the period. For reporting periods in which we have a net loss from continuing operations, the weighted-average anti-dilutive shares comprise shares that would have been dilutive had we had net income from continuing operations (e.g., convertible preferred stock, preferred stock dividends, restricted stock, warrants and stock options that have exercise prices below the average stock price for the period), plus the number of stock options that would be anti-dilutive had we had a net income from continuing operations.
Share-Based Compensation	'
	Share-Based Compensation
	We recognize share-based compensation expense based upon the fair value of the underlying equity award on the date of the grant. For restricted stock awards and restricted stock units, we recognize expense based upon the price of our underlying stock at the date of the grant. We have elected to use the Black-Scholes option pricing model to value any option or warrant awards granted. We amortize share-based compensation for such awards on a straight-line basis over the related service period of the awards taking into account the effects of the employees’ expected exercise and post-vesting employment termination behavior. To compute the volatility used in this model we use the historical volatility of our common stock over the expected life of options granted. The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. The expected life and estimated post-employment termination behavior is based upon historical experience of homogeneous groups within our company. We also assume an expected dividend yield of zero for all periods, as we have never paid a dividend on our common stock and do not have any plans to do so in the future.
Intangible Assets and Other Long Lived Assets	'
	Intangible Assets and Other Long Lived Assets
	Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair market value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair market value, less cost to sell.
Reclassifications	'
	Reclassifications
	Certain prior year amounts have been reclassified to conform to the current year presentation.
Accounting Renouncements	'
	Accounting Renouncements
	The FASB issued ASU 2014-09 "Revenue from Contracts with Customers" clarifying the method used to determine the timing and requirements for revenue recognition on the statements of income. Under the new standard, an entity must identify the performance obligations in a contract, the transaction price and allocate the price to specific performance obligations to recognize the revenue when the obligation is completed. The amendments in this update also require disclosure of sufficient information to allow users to understand the nature, amount, timing and uncertainty of revenue and cash flow arising from contracts. The new accounting guidance is effective for interim and annual periods beginning after December 15, 2016. We are analyzing the impact of this new standard and, at this time, cannot estimate the impact of adoption on revenue or net income. We plan to adopt ASU 2014-09 effective January 1, 2017.

Basis_of_Presentation_and_Sign2

Basis of Presentation and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Earnings Per Share	'
	Earnings Per Share
		Net loss per share from continuing													Net (loss)/income attributable to common stockholders
		operations
		For the three months ended September 30,							For the nine months ended September 30,						For the three months ended September 30,						For the nine months ended September 30,
		2014				2013			2014			2013			2014			2013			2014		2013
	Numerator:
	Net loss from continuing operations	$	(466,556	)		$	(774,579	)	$	(2,184,989	)	$	(3,128,846	)
	Net (loss)/income attributable to stockholders														$	(770,930	)	$	(640,078	)	$	6,796,522	$	1,143,442
	Denominator:
	Basic weighted average common shares outstanding	15,016,429				14,441,707			14,821,619			14,285,829			15,016,429			14,441,707			14,821,619		14,285,829
	Weighted average common stock equivalents from assumed exercise of stock options and restricted stock awards	—				—			—			—			—			—			688,065		730,703
	Convertible preferred stock	—				—			—			—			—			—			1,321,514		1,321,514
	Preferred stock dividends	—				—			—			—			—			—			354,171		255,056
	Diluted weighted average common shares outstanding	15,016,429				14,441,707			14,821,619			14,285,829			15,016,429			14,441,707			17,185,369		16,593,102
	Basic net loss per share from continuing operations	$	(0.03	)		$	(0.05	)	$	(0.15	)	$	(0.22	)
	Diluted net loss per share from continuing operations	$	(0.03	)		$	(0.05	)	$	(0.15	)	$	(0.22	)
	Basic net (loss)/income per share attributable to common stockholders														$	(0.05	)	$	(0.04	)	$	0.46	$	0.08
	Diluted net (loss)/income per share attributable to common stockholders														$	(0.05	)	$	(0.04	)	$	0.4	$	0.07
	Weighted-average anti-dilutive shares related to:
	Outstanding stock options	4,448,259				5,322,656			4,086,208			5,322,686			4,448,259			5,322,656			3,005,297		4,095,725
	Convertible preferred stock	1,321,514				1,321,514			1,321,514			1,321,514			1,321,514			1,321,514			—		—
	Preferred stock dividends	373,994				274,879			354,171			255,056			373,994			274,879			—		—
	Restricted stock	330,160				261,257			290,394			219,759			330,160			261,257			—		—
	Carilion warrants	366,000				366,000			366,000			366,000			366,000			366,000			366,000		366,000
Assumptions Used to Estimate Fair Value of Option Granted	'
	The fair value of each option granted during the nine months ended September 30, 2014 and 2013 was estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions:
		Nine Months Ended September 30, 2014		Nine Months Ended September 30, 2013
	Risk-free interest rate	2.14%		1.27 - 2.34%
	Expected life of options (in years)	7.5		7.5
	Expected stock price volatility	106%		108%
Summary of Activity of 2003 Stock Plan and 2006 Equity Incentive Plan	'
	A summary of the activity for our 2003 Stock Plan and 2006 Equity Incentive Plan is presented below for the nine months ended September 30, 2014:
		Options Outstanding											Options Exercisable
		Number of			Price per Share		Weighted			Aggregate			Number of		Weighted			Aggregate
		Shares			Range		Average			Intrinsic			Shares		Average			Intrinsic
							Exercise			Value (1)					Exercise			Value (1)
							Price								Price
	Balance, January 1, 2014	5,279,229			$0.35 - $6.55		$	2.11		$	784,154		4,012,378		$	2.28		$	697,826
	Granted	915,952			$1.37 - $1.53		$	1.42
	Exercised	(276,586	)		$0.35 - $1.27		$	0.79
	Canceled	(1,470,336	)		$0.35 - $6.55		$	1.4
	Balance, September 30, 2014	4,448,259			$0.35 - $6.55		$	1.92		$	494,279		3,055,457		$	2.11		$	459,175
	-1	The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only. The aggregate intrinsic value is based on the closing price of our common stock on the NASDAQ Capital Market, as applicable, on the respective dates.

Discontinued_Operations_Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2014
Discontinued Operations and Disposal Groups [Abstract]	'
Components of (Loss)/Income from Discontinued Operations	'
	The key components of income from discontinued operations were as follows:
		Three Months Ended						Nine Months Ended
		30-Sep-14			30-Sep-13			30-Sep-14			30-Sep-13
	Net revenues	$	—		$	1,578,308		$	—		$	4,343,391
	Cost of revenues	—			927,847			46,204			2,623,286
	Operating expenses	—			—			—			229,745
	Income/(loss) before income taxes	—			650,461			(46,204		)	1,490,360
	Allocated tax expense/(benefit)	52			255,905			(18,077		)	590,181
	Operating (loss)/income from discontinued operations, net of income taxes	(52		)	394,556			(28,127		)	900,179
	(Loss)/gain on sale, net of $0.3 million, $0.2 million, $1.6 million and $1.5 million of related income taxes	(277,562		)	(233,889		)	9,093,268			3,448,270
	(Loss)/income from discontinued operations, net of income taxes	$	(277,614	)	$	160,667		$	9,065,141		$	4,348,449

Inventory_Tables

Inventory (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Components of Inventory	'
	Components of inventory are as follows:
		September 30,		December 31,
		2014		2013
	Finished goods	$	637,054	$	719,574
	Work-in-process	452,304		361,754
	Parts	2,518,037		2,339,595
		3,607,395		3,420,923
	Less: Inventory reserves	207,263		74,746
	Total inventory, net	$	3,400,132	$	3,346,177

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities	'
		30-Sep-14		31-Dec-13
	Accrued compensation	$	2,111,858	$	2,205,612
	Accrued sub-contracts	309,570		297,510
	Accrued professional fees	20,885		279,991
	Accrued income tax	162,105		13,143
	Deferred rent	72,477		102,569
	Royalties	344,383		291,442
	Warranty reserve	61,850		56,700
	Claims reserve	—		92,167
	Accrued liabilities - other	375,328		207,451
	Total Accrued Liabilities	$	3,458,456	$	3,546,585

Capital_Stock_and_Additional_P1

Capital Stock and Additional Paid-in Capital (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Equity Transactions	'
	The following details our equity transactions during the nine months ended September 30, 2014:
		Preferred Stock		Common Stock		Treasury Stock				Additional
										Paid-in
										Capital
		Shares	$	Shares	$	Shares		$		$
	Balances, December 31, 2013	1,321,514	1,322	14,527,335	14,842	—		—		62,756,571
	Exercise of stock options	—	—	276,586	277	—		—		217,668
	Share-based compensation	—	—	268,500	209	—		—		766,724
	Stock dividends to Carilion Clinic(1)	—	—	—	59	—		—		83,572
	Purchase of treasury stock					(22,725	)	(32,221	)
	Balances, September 30, 2014	1,321,514	1,322	15,072,421	15,387	(22,725	)	(32,221	)	63,824,535
	-1	The stock dividends payable in connection with Carilion Clinic’s Series A Preferred Stock will be issued subsequent to September 30, 2014. For the period from January 12, 2010, the original issue date of the Series A Preferred Stock, through September 30, 2014, the Series A Preferred Stock issued to Carilion has accrued $793,807 in dividends. The accrued and unpaid dividends as of September 30, 2014 will be paid by the issuance of 373,994 shares of our common stock upon Carilion’s written request.

Operating_Segments_Tables

Operating Segments (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of revenues, operating loss and assets for reportable segments	'
	The table below presents revenues and operating loss for reportable segments not including discontinued operations:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
		(unaudited)						(unaudited)
	Revenues:
	Technology development revenues	$	3,067,022		$	3,130,206		$	8,961,909		$	8,564,743
	Products and licensing revenues	2,303,508			1,568,646			6,108,799			5,070,441
	Total revenues	$	5,370,530		$	4,698,852		$	15,070,708		$	13,635,184
	Technology development operating loss	$	(299,980	)	$	(259,486	)	$	(2,835,120	)	$	(599,303	)
	Products and licensing operating loss	(420,010		)	(1,042,526		)	(800,240		)	(4,683,929		)
	Total operating loss	$	(719,990	)	$	(1,302,012	)	$	(3,635,360	)	$	(5,283,232	)
	Depreciation, technology development	$	49,592		$	86,413		$	160,327		$	272,570
	Depreciation, products and licensing	$	37,247		$	43,304		$	109,037		$	161,426
	Amortization, technology development	$	38,641		$	61,563		$	131,615		$	173,140
	Amortization, products and licensing	$	29,022		$	30,851		$	90,087		$	104,239
	The table below presents assets for reportable segments:
		September 30,			December 31,
		2014			2013
	Total segment assets:
	Technology development	$	14,902,005		$	10,208,433
	Products and licensing	11,192,253			9,495,642
	Total	$	26,094,258		$	19,704,075
	Property plant and equipment, and intangible assets, technology development	$	1,198,066		$	1,217,083
	Property plant and equipment, and intangible assets, products and licensing	$	899,816		$	1,132,101

Basis_of_Presentation_and_Sign3

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
			Segment
Accounting Policies [Abstract]	'	'	'	'	'
Number of operating segments	'	'	2	'	'
Expected dividend yield of stock options	'	'	0.00%	0.00%	'
Outstanding stock options (in shares)	4,448,259	'	4,448,259	'	5,279,229
Outstanding stock options, weighted average remaining contractual term	'	'	'6 years 3 months 4 days	'	'
Exercisable stock options (in shares)	3,055,457	'	3,055,457	'	4,012,378
Exercisable stock options, weighted average remaining contractual term	'	'	'5 years 18 days	'	'
Stock-based compensation	$300,000	$300,000	$738,802	$896,554	'
Stock-based compensation expense expected to recognize	$1,600,000	'	$1,600,000	'	'
Weighted average remaining service	'	'	'1 year 7 months 24 days	'	'
Stock repurchased during period, shares	'	'	22,725	'	'
Average share price of repurchased stock (in usd per share)	'	'	$1.42	'	'

Basis_of_Presentation_and_Sign4

Basis of Presentation and Significant Accounting Policies - Per Share Net Loss from Continuing Operations and Net (Loss)/Income Attributable to Common Stockholders (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Numerator:	'	'	'	'
Net loss from continuing operations	($466,556)	($774,579)	($2,184,989)	($3,128,846)
Net (loss)/income attributable to stockholders	($770,930)	($640,078)	$6,796,522	$1,143,442
Denominator:	'	'	'	'
Basic weighted average common shares outstanding	15,016,429	14,441,707	14,821,619	14,285,829
Weighted average common stock equivalents from assumed exercise of stock options and restricted stock awards (in shares)	'	'	688,065	730,703
Convertible preferred stock (in shares)	'	'	1,321,514	1,321,514
Preferred stock dividends (in shares)	'	'	354,171	255,056
Diluted weighted average common shares outstanding	15,016,429	16,809,498	17,185,369	16,593,102
Diluted weighted average common shares outstanding	15,016,429	14,441,707	17,185,369	16,593,102
Basic net loss per share from continuing operations (in dollars per share)	($0.03)	($0.05)	($0.15)	($0.22)
Diluted net loss per share from continuing operations (in dollars per share)	($0.03)	($0.05)	($0.15)	($0.22)
Basic net income per share attributable to common stockholders (in dollars per share)	($0.05)	($0.04)	$0.46	$0.08
Diluted net income per share attributable to common stockholders (in dollars per share)	($0.05)	($0.04)	$0.40	$0.07
Outstanding stock options	'	'	'	'
Denominator:	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	4,448,259	5,322,656	3,005,297	4,095,725
Convertible preferred stock	'	'	'	'
Denominator:	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	1,321,514	1,321,514	0	0
Preferred stock dividends	'	'	'	'
Denominator:	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	373,994	274,879	0	0
Restricted stock	'	'	'	'
Denominator:	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	330,160	261,257	0	0
Carilion warrants	'	'	'	'
Denominator:	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	366,000	366,000	366,000	366,000
Continuing Operations	'	'	'	'
Denominator:	'	'	'	'
Basic weighted average common shares outstanding	15,016,429	14,441,707	14,821,619	14,285,829
Diluted weighted average common shares outstanding	15,016,429	14,441,707	14,821,619	14,285,829
Continuing Operations | Outstanding stock options	'	'	'	'
Denominator:	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	4,448,259	5,322,656	4,086,208	5,322,686
Continuing Operations | Convertible preferred stock	'	'	'	'
Denominator:	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	1,321,514	1,321,514	1,321,514	1,321,514
Continuing Operations | Preferred stock dividends	'	'	'	'
Denominator:	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	373,994	274,879	354,171	255,056
Continuing Operations | Restricted stock	'	'	'	'
Denominator:	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	330,160	261,257	290,394	219,759
Continuing Operations | Carilion warrants	'	'	'	'
Denominator:	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	366,000	366,000	366,000	366,000

Basis_of_Presentation_and_Sign5

Basis of Presentation and Significant Accounting Policies - Assumptions Used to Estimate Fair Values of Option Granted (Detail)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate	2.14%	'
Expected life of options (in years)	'7 years 6 months	'7 years 6 months
Expected stock price volatility	106.00%	108.00%
Minimum	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate	'	1.27%
Maximum	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate	'	2.34%

Basis_of_Presentation_and_Sign6

Basis of Presentation and Significant Accounting Policies - Summary of Activity of 2003 stock Plan and 2006 Equity Incentive Plan (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Options Outstanding, Number of Shares	'
Beginning Balance (in shares)	5,279,229
Granted (in shares)	915,952
Exercised (in shares)	-276,586
Canceled (in shares)	-1,470,336
Ending Balance (in shares)	4,448,259
Options Outstanding, Price per Share Range	'
Beginning Balance, lower limit (in dollars per share)	$0.35
Beginning Balance, upper limit (in dollars per share)	$6.55
Granted, lower limit (in dollars per share)	$1.37
Granted, upper limit (in dollars per share)	$1.53
Exercised, lower limit (in dollars per share)	$0.35
Exercised, upper limit (in dollars per share)	$1.27
Canceled, lower limit (in dollars per share)	$0.35
Canceled, upper limit (in dollars per share)	$6.55
Balance, lower limit (in dollars per share)	$0.35
Balance, upper limit (in dollars per share)	$6.55
Options Outstanding, Weighted Average Exercise Price	'
Beginning Balance (in dollars per share)	$2.11
Granted (in dollars per share)	$1.42
Exercised (in dollars per share)	$0.79
Canceled (in dollars per share)	$1.40
Ending Balance (in dollars per share)	$1.92
Options Outstanding, Aggregate Intrinsic Value, Beginning Balance	$784,154	[1]
Options Outstanding, Aggregate Intrinsic Value, Ending Balance	494,279	[1]
Options Exercisable, Beginning Balance (in shares)	4,012,378
Options Exercisable, Ending Balance (in shares)	3,055,457
Options Exercisable, Weighted Average Exercise Price, Beginning Balance (in dollars per share)	$2.28
Options Exercisable, Weighted Average Exercise Price, Ending Balance (in dollars per share)	$2.11
Options Exercisable, Aggregate Intrinsic Value, Beginning Balance	697,826	[1]
Options Exercisable, Aggregate Intrinsic Value, Ending Balance	$459,175	[1]
[1]	The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only. The aggregate intrinsic value is based on the closing price of our common stock on the NASDAQ Capital Market, as applicable, on the respective dates.

Discontinued_Operations_Additi

Discontinued Operations - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

Mar. 01, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Mar. 01, 2013

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Mar. 01, 2013

Feb. 28, 2013

Jan. 21, 2014

Jan. 21, 2014

Jan. 20, 2014

Oct. 31, 2014

Revenues

Cost of Revenues

Secure Computing and Communications Group (SCC)

Secure Computing and Communications Group (SCC)

Secure Computing and Communications Group (SCC)

Secure Computing and Communications Group (SCC)

Secure Computing and Communications Group (SCC)

Secure Computing and Communications Group (SCC)

Medical Shape Sensing Business

Medical Shape Sensing Business

Medical Shape Sensing Business

Subsequent Event

Employee

Secure Computing and Communications Group (SCC)

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale price to an unaffiliated third party

'

'

'

'

'

'

'

'

'

'

'

$6,100,000

'

'

$30,000,000

'

'

Purchase price receivable on sale of disposal group

'

'

'

'

'

'

'

'

110,000

'

110,000

5,400,000

'

'

'

'

'

Purchase price received from escrow

'

'

'

'

'

'

'

'

475,000

'

'

'

'

'

'

'

125,000

Transaction costs incurred related to disposal group sales

'

'

'

'

'

'

'

900,000

'

'

'

'

'

1,300,000

'

'

'

Sublease income

'

'

'

'

'

'

'

'

'

106,000

'

'

'

'

'

'

'

Employees of disposal group transferred to purchaser

'

'

'

'

'

'

'

'

'

'

'

20

'

'

'

'

'

Current assets related to disposal group

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

Long-term assets related to disposal group

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

300,000

'

Gain on sale, net of income taxes

'

-277,562

-233,889

9,093,268

3,448,270

'

'

'

'

'

3,300,000

'

'

'

'

'

'

Net income per share from discontinued operations, diluted (in dollars per share)

$0.53

($0.02)

$0.01

$0.53

$0.26

'

'

'

'

'

$0.20

'

'

'

'

'

'

Cash consideration received at closing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,000,000

'

'

Cash consideration received in future tied to achievement of technical specifications

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,000,000

'

'

Cash consideration received in future, potential future royalties

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10,000,000

'

'

Disposal group accounted percentage of revenue and cost of revenue

'

'

'

'

'

12.00%

10.00%

'

'

'

'

'

'

'

'

'

'

Discontinued_Operations_Compon

Discontinued Operations - Components of (Loss) Income from Discontinued Operations (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Discontinued Operations and Disposal Groups [Abstract]	'	'	'	'
Net revenues	$0	$1,578,308	$0	$4,343,391
Cost of revenues	0	927,847	46,204	2,623,286
Operating expenses	0	0	0	229,745
Income/(loss) before income taxes	0	650,461	-46,204	1,490,360
Allocated tax expense/(benefit)	52	255,905	-18,077	590,181
Operating (loss)/ income from discontinued operations	-52	394,556	-28,127	900,179
(Loss)/gain on sale, net of $0.3 million, $0.2 million, $1.6 million and $1.5 million of related income taxes	-277,562	-233,889	9,093,268	3,448,270
(Loss)/income from discontinued operations, net of income taxes	($277,614)	$160,667	$9,065,141	$4,348,449

Discontinued_Operations_Compon1

Discontinued Operations - Components of (Loss) Income from Discontinued Operations (Parenthetical) (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Discontinued Operations and Disposal Groups [Abstract]	'	'	'	'
Gain on sale, related income taxes	$281,462	$233,889	$1,604,883	$1,491,677

Inventory_Components_of_Invent

Inventory - Components of Inventory (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]	'	'
Finished goods	$637,054	$719,574
Work-in-process	452,304	361,754
Parts	2,518,037	2,339,595
Total inventory, gross	3,607,395	3,420,923
Less: Inventory reserves	207,263	74,746
Total inventory, net	$3,400,132	$3,346,177

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]	'	'
Accrued compensation	$2,111,858	$2,205,612
Accrued sub-contracts	309,570	297,510
Accrued professional fees	20,885	279,991
Accrued income tax	162,105	13,143
Deferred rent	72,477	102,569
Royalties	344,383	291,442
Warranty reserve	61,850	56,700
Claims reserve	0	92,167
Accrued liabilities - other	375,328	207,451
Total Accrued Liabilities	$3,458,456	$3,546,585

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Oct. 15, 2014	Sep. 30, 2014	Jan. 21, 2014	Mar. 21, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
			Letter of Credit	Term Loan	Revolving Credit Facility	Revolving Credit Facility	Revolving Credit Facility	Revolving Credit Facility	Silicon Valley Bank
			Subsequent Event	Installment	Fourth Loan Modification Agreement	Fourth Loan Modification Agreement	Silicon Valley Bank Term Loan	Silicon Valley Bank Term Loan	Term Loan
							Second and Third Amendment	Second and Third Amendment
								Monthly Payment
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Debt, face amount	'	'	'	$6,000,000	'	'	'	'	'
Debt, number of monthly payment	'	'	'	48	'	'	'	'	'
Debt, frequency of periodic payment	'	'	'	'monthly	'	'	'	'	'
Debt, additional interest above prime rate	'	'	'	2.00%	'	'	1.25%	'	'
Debt Instrument, Interest Rate During Period	'	'	'	6.00%	'	'	'	'	'
Credit facility, maximum borrowing capacity	'	'	'	'	'	'	1,000,000	'	'
Unused Line of Credit fee percentage	'	'	'	'	'	'	'	0.25%	'
Frequency of commitment fee payment	'	'	'	'	'	'	'	'monthly	'
Credit facility, maturity date	'	'	'	'	'	'	17-May-14	'	'
Maintaining minimum cash balance as per covenant	'	'	'	'	3,000,000	5,000,000	'	'	'
Line of Credit Facility, Borrowing Requested in Connection with Lease Financing	'	'	500,000	'	'	'	'	'	'
Long-term debt obligation	$1,000,000	$1,500,000	'	'	'	'	'	'	$1,000,000

Capital_Stock_and_Additional_P2

Capital Stock and Additional Paid-in Capital (Detail) (USD $)	9 Months Ended			9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014		Sep. 30, 2014	Sep. 30, 2014
		Preferred Stock	Preferred Stock	Common Stock		Treasury Stock	Additional Paid-in Capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'		'	'
Balances, December 31, 2013 (in shares)	1,321,514	1,321,514	1,321,514	'		'	'
Balances, December 31, 2013 (in shares)	14,527,335	'	'	14,527,335		'	'
Balances, December 31, 2013	$11,762,378	$1,322	$1,322	$14,842		$0	$62,756,571
Balances, December 31, 2013 (in shares)	0	'	'	'		0	'
Exercise of stock options (in shares)	276,586	'	'	276,586		'	'
Exercise of stock options	'	'	'	277		'	217,668
Share-based compensation (in shares)	'	'	'	268,500		'	'
Share-based compensation	'	'	'	209		'	766,724
Stock dividends to Carilion Clinic	'	'	'	59	[1]	'	83,572	[1]
Purchase of treasury stock (in shares)	-22,725	'	'	'		-22,725	'
Purchase of treasury stock	'	'	'	'		-32,221	'
Balances, September 30, 2014 (in shares)	1,321,514	1,321,514	1,321,514	'		'	'
Balances, September 30, 2014 (in shares)	15,026,973	'	'	15,072,421		'	'
Balances, September 30, 2014 (in shares)	-22,725	'	'	'		-22,725	'
Balances, September 30, 2014	$19,595,188	$1,322	$1,322	$15,387		($32,221)	$63,824,535
[1]	The stock dividends payable in connection with Carilion Clinicbs Series A Preferred Stock will be issued subsequent to SeptemberB 30, 2014. For the period from JanuaryB 12, 2010, the original issue date of the Series A Preferred Stock, through SeptemberB 30, 2014, the Series A Preferred Stock issued to Carilion has accrued $793,807 in dividends. The accrued and unpaid dividends as of SeptemberB 30, 2014 will be paid by the issuance of 373,994 shares of our common stock upon Carilionbs written request.

Capital_Stock_and_Additional_P3

Capital Stock and Additional Paid-in Capital (Parenthetical) (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Stockholders Equity Note [Line Items]	'
Accrued dividends	793,807
Carilion Clinic | Series A Preferred Stock	'
Stockholders Equity Note [Line Items]	'
Stock dividends for preferred shareholders	373,994

Operating_Segments_Additional_

Operating Segments - Additional Information (Detail)	9 Months Ended	12 Months Ended	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
	Segment	Sales	Sales	Sales	Sales	Sales	Sales	Sales	Sales	Sales
			International	International	International	International	United States Government	United States Government	United States Government	United States Government
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Number of operating segments	2	'	'	'	'	'	'	'	'	'
Percentage of total consolidated revenues by customer	'	12.00%	'	'	'	'	60.00%	62.00%	60.00%	56.00%
Percentage of total consolidated revenues	'	'	15.00%	16.00%	16.00%	23.00%	'	'	'	'

Operating_Segments_Revenues_an

Operating Segments - Revenues and Operating Loss for Reportable Segments Not Including Discontinued Operations (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Technology development revenues	$3,067,022	$3,130,206	$8,961,909	$8,564,743
Products and licensing revenues	2,303,508	1,568,646	6,108,799	5,070,441
Total revenues	5,370,530	4,698,852	15,070,708	13,635,184
Total operating loss	-719,990	-1,302,012	-3,635,360	-5,283,232
Technology Development	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total operating loss	-299,980	-259,486	-2,835,120	-599,303
Depreciation	49,592	86,413	160,327	272,570
Amortization	38,641	61,563	131,615	173,140
Products and Licensing	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total operating loss	-420,010	-1,042,526	-800,240	-4,683,929
Depreciation	37,247	43,304	109,037	161,426
Amortization	$29,022	$30,851	$90,087	$104,239

Operating_Segments_Assets_for_

Operating Segments - Assets for Reportable Segments (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Assets	$26,094,258	$19,704,075
Property plant and equipment, and intangible assets	1,917,164	2,060,709
Technology Development	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Assets	14,902,005	10,208,433
Property plant and equipment, and intangible assets	1,198,066	1,217,083
Products and Licensing	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Assets	11,192,253	9,495,642
Property plant and equipment, and intangible assets	$899,816	$1,132,101

Contingencies_and_Guarantees_A

Contingencies and Guarantees - Additional information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2014
	purchase_order
Loss Contingencies [Line Items]	'	'
Number of non-cancelable purchase orders executed	2	'
Non-cancelable purchase order commitment	$1.40	'
Non-cancelable purchase order delivery period	'18 months	'
Non-cancelable purchase order commitment remained	'	0.7
Defense Contract Audit Agency | Preliminary Audit Report	'	'
Loss Contingencies [Line Items]	'	'
Claimed cost, subject to potential penalty	'	$0.80